ZoneOne Pharma (United States)
- Research works
- 31 ▲ 137% vs 2013–17
- Citations
- 694 22.3 per fractional work
- Top-10% rate
- 5.6% record average 16.5%
- Open access
- 45% world 28%
Not ranked overall: ZoneOne Pharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 6.3×. Every wedge is a field page.
- Economics, Econometrics and Finance 6.3×
- Immunology and Microbiology 4.6×
- Biochemistry, Genetics and Molecular Biology 4.6×
- Materials Science 1.9×
- Medicine 1.1×
- Computer Science 0.9×
- Arts and Humanities 0.8×
- Engineering 0.8×
- Environmental Science 0.5×
- Business, Management and Accounting 0.5×
- Social Sciences 0.3×
- Neuroscience 0.2×
- Psychology 0.1×
Which keywords describe research at ZoneOne Pharma (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Inflammation, Anticancer Agents, Drug Development, Clinical Trials, Apoptosis, Epidemiology and Molecular Mechanisms.
- Molecular Mechanisms
- Cardiovascular Disease
- Clinical Trials
- Anticancer Agents
- Inflammation
- Epidemiology
- Cancer Therapy
- Cancer
- Apoptosis
- Drug Development
- Synthesis
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 11 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 11 words, with their numbers
- Epidemiology2▲ 1.74×12 topics
- Inflammation2▲ 3.0×10 topics
- Cancer Therapy2▲ 9.0×5 topics
- Anticancer Agents1▲ 17×2 topics
- Cancer1▲ 2.9×6 topics
- Clinical Trials1▲ 6.1×6 topics
- Apoptosis1▲ 8.7×4 topics
- Cardiovascular Disease1▲ 3.2×4 topics
- Drug Development1▲ 24×3 topics
- Molecular Mechanisms1▲ 18×2 topics
- Synthesis1▲ 5.5×2 topics
Which research topics does ZoneOne Pharma (United States) publish most on?
By volume in 2022–2025: Protein Degradation and Inhibitors, Cancer-related Molecular Pathways, Health Systems, Economic Evaluations, Quality of Life and Cancer Research and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Protein Degradation and Inhibitors Molecular Biology 1 works
- 2 Cancer-related Molecular Pathways Oncology 0 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
- 4 Cancer Research and Treatments Biotechnology 0 works
- 5 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
- 6 Nanoparticle-Based Drug Delivery Biomaterials 0 works
- 7 Receptor Mechanisms and Signaling Molecular Biology 0 works
- 8 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 0 works
- 9 Ubiquitin and proteasome pathways Molecular Biology 0 works
- 10 Microstructure and Mechanical Properties of Steels Mechanical Engineering 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has ZoneOne Pharma (United States)'s research output changed?
Output in 2018–2022 was 137% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in San Francisco
- University of California, San Francisco
- San Francisco State University
- University of San Francisco
- San Francisco VA Medical Center
- University of California San Francisco Medical Center
- San Francisco General Hospital
- Institute on Aging
- California Pacific Medical Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.